iwCLL 2019 | Clonal evolution and resistance mechanisms to BCL-2 receptor inhibition

Mary Ann Anderson

Mary Ann Anderson, MBBS, Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia, discusses the development of resistance to BCL-2 receptor inhibition, and what it means for treatment strategies. This interview took place at the 18th International Workshop on Chronic Lymphocytic Leukemia (iwCLL) Biennial Meeting, held in Edinburgh, UK.

Share this video